Paracoccidioidomycosis
ICD-10 B41.0 is a billable code used to indicate a diagnosis of paracoccidioidomycosis.
Paracoccidioidomycosis is a systemic fungal infection caused by the dimorphic fungus Paracoccidioides brasiliensis, primarily endemic to regions of Central and South America. The disease typically presents with pulmonary symptoms, but can also affect the skin, mucous membranes, lymph nodes, and other organs. Initial infection often occurs through inhalation of spores, leading to a primary pulmonary form that may remain asymptomatic or progress to chronic pulmonary disease. In immunocompromised patients, such as those with HIV/AIDS, the disease can disseminate more rapidly and severely, leading to complications such as respiratory failure or systemic involvement. Diagnosis is confirmed through clinical evaluation, imaging studies, and laboratory tests, including culture and serological assays. Treatment typically involves antifungal medications such as itraconazole or amphotericin B, depending on the severity of the disease and the patient's immune status. Early diagnosis and appropriate antifungal therapy are crucial to improving outcomes and preventing complications.
Detailed patient history, including travel and exposure history, clinical findings, and laboratory results.
Patients presenting with respiratory symptoms, skin lesions, or systemic symptoms in endemic areas.
Consideration of immunocompromised status and potential for co-infections.
Pulmonary function tests, imaging studies, and treatment response documentation.
Patients with chronic cough, hemoptysis, or pulmonary nodules.
Differentiation from other chronic pulmonary diseases.
Used for confirming the diagnosis of paracoccidioidomycosis.
Document the reason for the culture and any relevant clinical findings.
Infectious disease specialists should ensure comprehensive documentation of clinical context.
Paracoccidioidomycosis is a systemic fungal infection caused by the fungus Paracoccidioides brasiliensis, primarily affecting individuals in endemic regions of Central and South America.
Treatment typically involves antifungal medications such as itraconazole or amphotericin B, depending on the severity of the disease and the patient's immune status.
Common symptoms include chronic cough, weight loss, fever, and skin lesions. In severe cases, it can lead to respiratory failure or systemic involvement.
